1 Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID PROFILE)

2	Emily M. Eriksson, ^{1,2#} Anne Hart, ¹ Maureen Forde, ¹ Siavash Foroughi, ^{1,2} Nicholas
3	Kiernan-Walker, ¹ Ramin Mazhari, ^{1,2} Erin C. Lucas, ¹ Mai Margetts, ¹ Anthony
4	Farchione, ¹ Dylan Sheerin, ^{1,2} George Ashdown, ^{1,2} Rachel Evans, ¹ Catherine Chen, ^{1,2}
5	Shazia Ruybal-Pesántez, ^{1,2,3} Eamon Conway, ^{1,2} Marilou H. Barrios, ^{1,2} Jasper
6	Cornish, ^{1,2} Maria Edmonds, ¹ Lee M. Henneken, ^{1,4} Lisa J. Ioannidis, ^{1,2} Sam W. Z.
7	Olechnowicz, ^{1,2} Ryan B. Munnings, ¹ Joanna R. Groom, ^{1,2} Diana S. Hansen, ^{1,2} Rory
8	Bowden, ^{1,2} Anna K. Coussens, ^{1,2,5} Jason A. Tye-Din, ^{1,2,4,6} Vanessa L. Bryant, ^{1,2,7} and
9	Ivo Mueller ^{1,2}
10	# Corresponding outbor
10	
11	
12	1. Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
13	2. The University of Melbourne, Department of Medical Biology, Parkville, VIC 3052,
14	Australia
15	3. MRC Centre for Global Infectious Disease Analysis, Department of Infectious
16	Disease Epidemiology, Imperial College London, UK
17	4. Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, VIC
18	3052, Australia
19	5. Wellcome Centre for Infectious Diseases Research in Africa, Department of
20	Pathology, Institute of Infectious Diseases and Molecular Medicine, University of
21	Cape Town, South Africa 3079.
22	6. Centre for Food & Allergy Research, Murdoch Children's Research Institute,
23	Parkville, VIC, Australia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 24 7. Dept Clinical Immunology and Allergy, The Royal Melbourne Hospital, Parkville,
- 25 3050
- 26
- 27
- 28 Corresponding Author:
- 29 Emily M. Eriksson
- 30 The Walter and Eliza Hall Institute of Medical Research
- 31 1G Royal Parade, Parkville, VIC 3052 Australia
- 32 Tel: +61 3 93452870
- 33 email: eriksson@wehi.edu.au

34 Abstract

Purpose: The COVID PROFILE cohort is a longitudinal clinical study based in Victoria Australia, which was established to understand immunity to SARS-CoV-2 in a *low transmission population setting* and to identify immunological markers of long-term immunity and immune-dysregulation after both infection and vaccination. Additionally, this cohort was established as a biobank resource for researchers to address other health-related immunological questions.

Participants: We enrolled 178 adult community members, including household contacts, who had either recovered from a SARS-CoV-2 infection or were SARS-CoV-2 naïve. Only participants ≥18 years of age and, in the case of female participants, non-pregnant women at the time of enrollment were included in the study. Detailed COVID-19 clinical data, vaccination status, medical history and demographics was collected.

Findings to date: At enrollment, we found that 87.8% of COVID-19 recovered 47 48 individuals were seropositive with detectable levels of anti-SARS-CoV-2 lgG antibodies. Seronegative COVID-19 recovered individuals included asymptomatic 49 individuals or participants that were enrolled more than 12 months after their COVID-50 19 diagnosis. Except for one individual who was seropositive at baseline despite a 51 previous SARS-CoV-2 PCR negative diagnosis, all household contacts and other 52 53 community members enrolled as SARS-CoV-2 PCR negative, were seronegative for all SARS-CoV-2-specific antibodies tested. The infection rate (re-infection or new 54 infection) during 24 months of the study was 42.7%, as determined by either rapid 55 antigen tests, PCRs or serology screens. Of the SARS-CoV-2 recovered participants, 56 32.6% reported ongoing symptoms at enrollment of which 47% had already 57 58 experienced ongoing symptoms for more than 12 weeks.

59 **Future Plans**: COVID PROFILE will be used to comprehensively understand temporal 60 immunity to SARS-CoV-2 and COVID-19 vaccines and to understand the impact of 61 host immunological composition on such immunity and symptom severity. Additionally, 62 studies focusing on understanding immunity following breakthrough infections and 63 immunological risk factors that contribute towards development of long COVID are 64 planned.

66 Limitations/Strengths of the study

67	•	Extensive clinical information is available and longitudinal samples (blood,
68		saliva and oropharyngeal swabs) collected at regular intervals up to 2.5 years
69		after initial enrolment.

- This low SARS-CoV-2 transmission population cohort, enables exploration of
 difference in both the acquisition and maintenance of naturally acquired and
 vaccine-induced immunity not confounded by prior, frequent and/or undetected
 exposures.
- Extensive biobank of numerous blood fractions and biospecimen enables
 further exploration of mucosal immunity, nasal microbiome and humoral and
 cellular immunity over time.
- The cohort may be limited in addressing research questions regarding
 outcomes and risk factors and their associations where low incidence is
 expected.

80

82 Introduction and Cohort description

The first case of SARS-CoV-2 recorded in Australia was on January 25th 2020, only 83 25 days after the first case had been reported to the World Health Organisation (1). 84 85 This was followed by intense national efforts to diminish and if possible, eliminate SARS-CoV-2 transmission. While transmission was not immediately contained and 86 resulted in a peak of confirmed SARS-CoV-2 positive cases in late March followed by 87 88 a second peak in July, community transmission was largely undetectable by October 2020 (2) (Fig. 1). This pandemic response, which included international and domestic 89 90 border closures, lockdowns and Australia's geographical inaccessibility resulted in overall comparatively low case numbers and thus a distinctively SARS-CoV-2 naïve 91 population prior to COVID-19 vaccine rollout in February 2021. Furthermore, unlike 92 93 the majority of populations across the world, the Australian population remained 94 largely unexposed until end of 2021 (Fig.1).

The COVID PROFILE study was launched in Melbourne, Victoria in October 2020 to 95 96 follow COVID-19 recovered individuals over a year of enrollment, being in a relatively unique position to understand longevity of immunity to SARS-CoV-2 infection where 97 risk of continuous re-exposure was low. This study was approved by the Walter and 98 Eliza Hall Institute (WEHI) and Melbourne Health Human Research Committees 99 100 (Projects 20/08 and RMH69108 respectively). All enrolled participants provided written 101 informed consent to participate in this study, in accordance with the Declaration of Helsinki. Most participants were enrolled between October 2020 and June 2021. 102 103 SARS-CoV-2 recovered participants were predominantly infected locally during the 104 second July-September 2020 infection wave (71.4%) and the remaining participants contracted SARS-CoV-2 from the first infection wave (March-May 2020) or were 105 106 infected overseas (Fig. 1). The only circulating SARS-CoV-2 variant at the time of

107 these infections was the ancestral (Wuhan) strain resulting in a homogenously exposed population (Fig. 1). The study visit schedule consisted of a baseline visit (at 108 enrollment), 4-6 weeks post-diagnosis where possible, followed by visits at 3, 6, 9 and 109 110 12 months post-enrollment (Fig. 2). Following the roll out of COVID-19 vaccines in Australia in Feb 2021, that consisted predominantly of ChAdOx1-S (AstraZeneca) or 111 BNT162b2 (Pfizer), participants already enrolled in the study were invited to continue 112 113 follow-up for up to 12 months after their second dose of vaccine. Additional SARS-114 CoV-2 naïve individuals were invited to take part in the study before their first COVID-115 19 vaccination and for these newly recruited participants, a baseline pre-vaccination sample was also collected. Post-vaccination follow-up visits consisted of sample 116 collection 2-4 weeks after each dose of vaccine and then 3, 6, 9 and 12 months after 117 118 the second dose, unless another exposure event such as an additional vaccination or breakthrough infection occurred. Follow-up was then extended for up to 12 months 119 after each exposure, following a visit schedule comparable to that previously defined 120 121 (Fig. 2). Biospecimens consisting of blood, saliva, and oropharyngeal swabs were collected at all visits where blood specimens were stored as serum, plasma, 122 cryopreserved peripheral blood mononuclear cells (PBMCs), frozen and fixed whole 123 blood and in some cases neutrophils. Oropharyngeal swabs were collected and stored 124 in sample preservation medium in their original tubes at -80°C until required. Detailed 125 COVID-19 clinical data, vaccination status, medical history and demographics (both 126 during acute infection and long-term follow up) was collected and study data were 127 managed using REDCap electronic data capture tools hosted by the Clinical 128 129 Translation Centre, WEHI, Parkville, Victoria, Australia (3, 4).

130

131 Participant demographics

To date, 178 participants have been recruited to the COVID PROFILE study following 132 advertising campaigns via social media, primary care networks and tertiary teaching 133 hospital. Seven participants failed to provide a baseline sample as specified in the 134 135 study schedule and were excluded from the study and all analyses (Fig. 3). Ninetyeight participants were SARS-CoV-2 recovered and 73 were SARS-CoV-2 naïve at 136 enrolment. The participants comprised 122 separate households: 88 households with 137 1 participant, 26 households with 2 participants, 1 household with 3 participants and 7 138 139 households with 4 participants. Gender distribution was 59.1% female (n = 101) in the 140 overall cohort and 63.3% female (n = 62) in the COVID-19-recovered group. Overall age distribution in the cohort ranged from 18 to 90 years of age with a median age of 141 46 years. Median age for the SARS-CoV-2 naïve group was 44 years (range 18 – 90 142 143 years) and 49 years for the SARS-CoV-2 recovered group (range 19 – 75 years, Fig. 4), which resemble the overall distribution of nationwide adult cases in 2020 (5). 144

145

146 Self-reported acute disease symptoms and duration were collected at enrolment and after subsequent breakthrough infections. Acute disease status was classified as 147 "severe disease" if hospitalisation was required due to the infection, regardless of 148 whether intubation or oxygen supplementation was necessary. All other participants 149 150 with any symptoms were categorised as mild/moderate (78.6%; n=77) or 151 asymptomatic (3.1%; n=3) in cases of self-reported absence of symptoms (Fig. 3). A substantial proportion of participants were categorised as severe (18.4%; n=18), which 152 was higher than the reported national rate of 12.5% hospitalisation in 2020 due to 153 154 COVID-19 (6).

155

156 COVID-19 vaccine status

During follow up most participants received at least 2 doses of COVID-19 vaccines (81.9%). The breakdown of vaccine type received as primary vaccination is summarised in **Fig. 5**. Participants predominately received Pfizer (60%, median age = 40.5 years) and AstraZeneca (37.1%, median age = 56.5 years) with only a few receiving Moderna-Spikevax (0.7%) or Novavax (2.1%). A subset of the vaccinated participants have also received a third (43.4%) and fourth (35.7%) dose of vaccine of either Pfizer or Moderna-Spikevax.

164 Findings to date

To establish the serostatus of participants, SARS-CoV-2-specific IgG antibodies were 165 166 measured at baseline for all participants using a Luminex multiplex assay (7). This assay measures antibodies that recognize and bind to full-length Spike, receptor-167 binding domain (RBD), S1, S2 and nucleoprotein, all based on the Wuhan variant 168 169 sequence. In addition, antibodies specific for seasonal coronavirus proteins (NL63, 170 HKU1, OC43 and 229E), tetanus toxoid and Influenza A (H1N1) were also measured as controls. Serostatus based on measured anti-SARS-CoV-2 antibody levels was 171 172 determined using a random forest classification algorithm. Most participants who had a PCR+ diagnosis at enrolment were seropositive (87.8%) at baseline. Amongst the 173 174 COVID-19 recovered individuals who had a PCR+ diagnosis but were seronegative at enrolment (n=12), three presented as asymptomatic individuals, four participants were 175 enrolled more than 12 months after their COVID-19 diagnosis and the remaining 176 177 seronegative individuals were within 6 months of diagnosis. The majority of individuals that were enrolled as PCR negative participants (99%) were also seronegative, with 178 only one participant who had previously had a negative PCR diagnosis shortly before 179 180 sample collection, was found to be seropositive.

As part of the extensive longitudinal clinical data collected for this study, a substantial proportion of SARS-CoV-2 recovered participants (32.6% of 98 SARS-CoV-2 recovered individuals) reported ongoing symptoms at the time of enrolment of which 47% had already experienced symptoms persisting for 12 weeks or longer, meeting the current criteria for long COVID (8).

187

The longitudinal design of our study captured multiple breakthrough infections (42.4%) in our participants over the course of 24 months. Most such detections came from rapid antigen tests (RATs), precluding the identification of the infecting variant. However, 98.3% of breakthrough infections coincided with the period during which Omicron was the dominant variant in Australia (9). Most breakthrough infections were detected after three COVID-19 vaccine doses (65.5%) but they also occurred after two (15.5%) and four (19%) doses of COVID-19 vaccines

195

196 Future plans

Sample collection is expected to be completed in June 2023 after which samples will 197 support in-depth analysis to understand temporal humoral and cellular responses to 198 infection, COVID-19 vaccines and breakthrough infections with different variants. We 199 200 have so far collected and bio banked > 8300 biospecimens, which include serum, 201 whole blood, oropharyngeal swabs, plasma, PBMCs and saliva samples across 1200 visits over 24 months. Furthermore, given the detailed medical history recorded and 202 the relatively high frequency of participants reporting long COVID in our cohort, 203 204 additional analyses are planned to explore specific biomarkers and underlying processes involved with this condition. 205

206

207 Patient and public involvement

208 The participants were not involved in the study's design or conclusions. Participants

- 209 were informed of serological results via email.
- 210

211 Limitations/Strengths

The COVID PROFILE is a cohort study where extensive clinical information is 212 213 available and longitudinal blood samples, saliva and oropharyngeal swabs collected 214 at regular intervals up to 2.5 years after initial enrolment will have been accumulated 215 at the completion of the study. This included samples collected in naive individuals with subsequent infection. Low SARS-CoV-2 transmission in Australia before January 216 2022, provides an opportunity to explore difference in both the acquisition and 217 218 maintenance of naturally acquired and vaccine-induced immunity (or a combination 219 thereof), as well as differences in vaccine response in people with a single or no previous exposure to SARS-CoV-2. This also provides a unique opportunity to support 220 221 research questions not confounded by prior, frequent and/or undetected exposures using a highly curated and clinically annotated biobank of samples. We anticipate the 222 COVID PROFILE cohort will also provide great value as a comparative cohort set to 223 other studies in high transmission countries. Our extensive biobank includes 224 225 numerous blood fractions and biospecimen types collected longitudinally, which 226 further enables the exploration of mucosal immunity, nasal microbiome and humoral 227 and cellular immunity over time. However, due to its relatively small size, the cohort may be limited in addressing research questions regarding outcomes and risk factors 228 229 and their associations where low incidence is expected.

- 230
- 231

232

Collaboration The authors are welcoming and encouraging research collaborations
using the COVID PROFILE samples for population and/or immunological questions.
Samples and/or data are available on reasonable request and researchers are
welcome to contact the research group for further information.

237

238 Data availability statement

Samples and/or data are available upon reasonable request. Research proposals for
future collaboration are welcome. Applicants for collaboration and more information
are encouraged to contact the corresponding author Dr. Emily M Eriksson (Email
address: eriksson@wehi.edu.au).

244 **References**

245 Shaban RZ, Li C, O'Sullivan MVN, Gerrard J, Stuart RL, Teh J, et al. COVID-19 in 1. 246 Australia: our national response to the first cases of SARS-CoV-2 infection during the early 247 biocontainment phase. Intern Med J. 2021;51(1):42-51. 248 https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-2. 249 glance-20-december-2020. [Available from: 250 https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-20-251 december-2020. 252 3. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap 253 consortium: Building an international community of software platform partners. J Biomed 254 Inform. 2019;95:103208. 255 4. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic 256 data capture (REDCap)--a metadata-driven methodology and workflow process for providing 257 translational research informatics support. J Biomed Inform. 2009;42(2):377-81. 258 5. https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-aglance-30-september-2020. [Available from: 259 260 https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-30-261 september-2020. 262 6. https://www.aihw.gov.au/reports/burden-of-disease/the-first-year-of-covid-19-in-263 australia/summary. [Available from: https://www.aihw.gov.au/reports/burden-of-264 disease/the-first-year-of-covid-19-in-australia/summary. 265 Mazhari R, Ruybal-Pesantez S, Angrisano F, Kiernan-Walker N, Hyslop S, Longley RJ, 7. 266 et al. SARS-CoV-2 Multi-Antigen Serology Assay. Methods Protoc. 2021;4(4). 267 Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Condition WHOCCDWGoP-C-. A 8. clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 268 269 2022;22(4):e102-e7. 270 https://ourworldindata.org/grapher/covid-variants-9. 271 bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS. [Available from: 272 https://ourworldindata.org/grapher/covid-variants-273 bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS. 274 https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-10. 275 glance-31-december-2021. 276

278 Figures and Figure Legends



279

Figure 1. Schematic of COVID-19 pandemic in Australia 2020-2022. Schematic

timeline showing daily reported cases in Australia (2, 10) between Feb 2020 to Jan

282 2022 with indicated dominant infective variant identified in reported cases over time

283 (9). Created with BioRender.com



285

286 Figure 2. Study design and participant visit schedule

SARS-CoV-2 recovered participants were enrolled and followed for up to 12 months 287 after enrollment with sample collection at baseline (at enrollment) and 3, 6, 9 and 12 288 289 months after enrollment (green line). SARS-CoV-2 naïve participants provided a baseline sample (purple line). Biospecimen samples were collected from COVID-19 290 vaccinated participants 2-4 weeks after each vaccine dose and then at 3, 6, 9 and 12 291 292 months after the final dose (purple and blue line). Samples were also collected 2-4 weeks after breakthrough infections and again at 3, 6, 9 and 12 months after the 293 diagnosis (pink line). Saliva, oropharyngeal swabs, serum and whole blood were 294 collected and stored after each visit. 295

296 Created with BioRender.com

Figure 3



298

Figure 3. Summary of participant categories. Cohort participants stratified based on infection status at enrollment. Further stratification of SARS-CoV-2 recovered individuals based on disease status.



303

Figure 4. Cohort age and gender profile. Participant age range is 18-90 years; blue:

305 male; orange: female.



Figure 5. Summary of vaccine status of participants. Cohort participants stratified
based on disease status at time of enrollment and vaccine status after two doses of
COVID-19 vaccine. Vaccine recipients were further stratified based on the type of
COVID-19 vaccine received; Pfizer (BNT162b2), AstraZeneca (ChAdOx1-S),
Moderna- Spikevax or Novavax.

Funding: This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. This work was supported by WHO Unity funds (2020/1085469-0) and WEHI Philanthropic funds. The funders had no role in study design, data collection and analysis.

318

Author Contributions: EME and IM conceived and initiated the study. EME, IM, VLB 319 320 and JATD were the principal investigators of the study. EME established study protocols and oversaw clinical, technical and data analysis staff. EME, RB and AKC 321 322 established sample processing procedures. EME and SF wrote the manuscript. AH and MF were study coordinators managing recruitment, enrolment, collected samples 323 and obtained clinical and demographic data. SF managed the Redcap database. 324 325 NKW, RM, ECL, MM, AF, DS, GA, RE, CC, MHB, JC, LJI, SWZO, and RBM provided 326 technical assistance. ME and LMH assisted with sample collection. SF, SRP and EC managed data analysis. IM, VLB, JATD, JRG, DSH, RB and AKC critically reviewed 327 328 the manuscript. All authors read and approved submission of the manuscript.

329

330 Acknowledgments

We gratefully acknowledge all the participants of this project and St Vincent's hospital nurses for assistance with home visits and sample collection. We also thank all administrative and communications staff and personnel for their support.